Jaguar8 commented on a stock · Nov 5, 2024 22:49

NEWE

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

ADC Therapeutics (NYSE: ADCT) announced two investigator-initiated study abstracts on ZYNLONTA accepted for presentation at the 66th ASH Annual Meeting. The Phase 2 study combining ZYNLONTA with rituximab in relapsed/refractory follicular lymphomashowed a 97.1% overall response rate among 35 patients, with an 80% best complete metabolic response rate. In a separate study for relapsed/refractory marginal zone lymphoma, ZYNLONTA as a single agent achieved an 85% overall response rate with 75% complete response rate in 20 evaluable patients. Both studies demonstrated safety profiles consistent with known ZYNLONTA data.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

5311 Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

6649

Followers

Following

72K

Visitors